BiotechTube
Home/Compugen/Joshua P. Pustilnik, Ph.D.
JP

Joshua P. Pustilnik, Ph.D.

SVP, Corporate Development

Compugen

Therapeutic Areas

OncologyImmuno-oncology

Compugen Pipeline

DrugIndicationPhase
COM701Solid Tumors (e.g., Platinum-Resistant Ovarian Cancer)Phase 1/2
COM902Solid TumorsPhase 1/2
BAT5506Undisclosed Solid TumorsPreclinical

Leadership Team at Compugen

AC
Anat Cohen-Dayag, Ph.D.
President, CEO & Director
HA
Henry Adewoye, M.D.
Chief Medical Officer
EN
Eran Natanson
Chief Financial Officer
MD
Michele D. Korfin
COO & Chief Commercial Officer
MG
Martin Gerrits
Chair of the Board
View full Compugen profile